{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06255028",
            "orgStudyIdInfo": {
                "id": "CNTY-101-151-01"
            },
            "organization": {
                "fullName": "Century Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study on CNTY-101 in Patients With Moderate to Severe Lupus (SLE)",
            "officialTitle": "The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Moderate to Severe Lupus",
            "acronym": "CALiPSO-1",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "study-on-cnty-in-patients-with-moderate-to-severe-lupus-sle"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-05",
            "studyFirstSubmitQcDate": "2024-02-05",
            "studyFirstPostDateStruct": {
                "date": "2024-02-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Century Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "CALiPSO-1 is a Phase 1, multi-center, dose-finding study to assess the safety and efficacy of CNTY-101 in patients with moderate to severe systemic lupus erythematosus."
        },
        "conditionsModule": {
            "conditions": [
                "Systemic Lupus Erythematosus"
            ],
            "keywords": [
                "CAR iNK",
                "CAR NK",
                "Cellular therapy",
                "Systemic Lupus Erythematosus",
                "Induced pluripotent stem cell (iPSC)",
                "Anti-CD19 therapy",
                "CNTY-101",
                "Autoimmune disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 26,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: Dose Escalation Phase",
                    "type": "EXPERIMENTAL",
                    "description": "Lymphodepleting chemotherapy (LDC) will be followed by administration of CNTY-101, administered 3 times over 3 weeks, during Cycle 1 (cycle length = 28 days), alone or with supplemental human recombinant interleukin 2 (IL-2).\n\nAfter completion of Cycle 1, CNTY-101 (without preceding LDC), administered 3 times over 3 weeks, during Cycle 2 (cycle length = 28 days), alone or with supplemental IL-2.",
                    "interventionNames": [
                        "Biological: CNTY-101",
                        "Biological: IL-2",
                        "Drug: Lymphodepleting Chemotherapy"
                    ]
                },
                {
                    "label": "Part 2: Dose Expansion Phase",
                    "type": "EXPERIMENTAL",
                    "description": "Treatment using the recommended phase 2 regimen (RP2R) confirmed during Part 1 of the study.",
                    "interventionNames": [
                        "Biological: CNTY-101",
                        "Biological: IL-2",
                        "Drug: Lymphodepleting Chemotherapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "CNTY-101",
                    "description": "CNTY-101 cells for intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation Phase",
                        "Part 2: Dose Expansion Phase"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "IL-2",
                    "description": "IL-2 subcutaneous (SC) injection",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation Phase",
                        "Part 2: Dose Expansion Phase"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Lymphodepleting Chemotherapy",
                    "description": "LDC as prespecified in the protocol.",
                    "armGroupLabels": [
                        "Part 1: Dose Escalation Phase",
                        "Part 2: Dose Expansion Phase"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs",
                    "timeFrame": "Up to 29 days"
                },
                {
                    "measure": "Percentage of Participants With Dose Limiting Toxicities (DLTs)",
                    "timeFrame": "Up to 28 days after first CNTY-101 infusion"
                },
                {
                    "measure": "Recommended Phase 2 Regimen (RP2R) With/Without IL-2",
                    "timeFrame": "Up to 29 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of Participants With TEAEs and Serious Adverse Events (SAEs)",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Percentage of Participants With Clinically Significant Laboratory Abnormalities and Severity of Laboratory Abnormalities",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Percentage of Participants With Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and Severity of CRS and ICANS",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Percentage of Participants With SLE - Responder Index 4 (SRI-4) Response",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "Percentage of Participants With Low Disease Activity by Lupus Low Disease Activity State (LLDAS)",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "Percentage of Participants in Remission as Measured by Definitions of Remission in SLE (DORIS) Remission",
                    "timeFrame": "Up to 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Participants must have a diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus for at least 6 months.\n2. Participants must have elevated anti- double stranded deoxyribonucleic acid (anti-dsDNA) and/or elevated anti-Smith antibody test at Screening (a single retest of previously positive participants who were negative at screening will be allowed).\n3. Participants with diabetes or hypothyroidism should have well-controlled disease, with stable medications for at least 4 weeks prior to screening.\n4. Participants who despite at least 2 lines of prior standard immunosuppressive therapies for \u226512 weeks have:\n\n   1. A Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of \u22658 (including at least 4 points from non-laboratory assessments; excluding alopecia, mucosal ulcers, and fever) and at least 2 British Isles Lupus Assessment Group B (BILAG B) organ system scores and/or\n   2. At least one British Isles Lupus Assessment Group A (BILAG A) organ system score, including cardiac (peri- or myocarditis), respiratory (pleuritis or lung involvement), vascular and renal\n\nExclusion Criteria:\n\n1. Unable to washout prohibited or maintain stable allowed SLE therapy for 4 weeks prior to LDC therapy.\n2. Participants on hemodialysis.\n3. Participants with active lupus nephritis (prior history of biopsy-documented International Society of Nephrology/Renal Pathology Society Class VI Lupus Nephritis).\n4. Recent or clinically significant central nervous system (CNS) disease, including but not limited to cerebrovascular accident, epilepsy, severe brain injury, dementia, Parkinson's disease, cerebellar disease, seizures, organic brain syndrome, lupus headache, or psychosis at any time prior to study.\n5. Participants with BILAG A for neuropsychiatric SLE.\n6. Thromboembolic events within last 12 months.\n7. Participants with severe hepatic dysfunction, defined as grade C-Child-Pugh.\n8. Diagnosis of drug-induced SLE rather than idiopathic SLE.\n9. Participants with either proteinuria \\>3 grams per day (g/day), or a urinary protein creatinine ratio (UPCR) of \\>3 grams per gram (g/g). At least 2 measurements of proteinuria or UPCR over the past 6 months is required to confirm control of renal disease.\n10. Study participant with chronic kidney failure stage 4, manifested by estimated glomerular filtration rate \\<45 milliliters per minute per 1.73 square meter (mL/min/1.73 m\\^2) (measured by Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation), or serum creatinine \\>2.5 milligrams per deciliter (mg/dL).",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "17 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nikolaus Trede",
                    "role": "CONTACT",
                    "phone": "8885067670",
                    "email": "calipso-1_clinicalteam@centurytx.com"
                }
            ],
            "locations": [
                {
                    "facility": "Lurie Children's; Northwestern Medicine - Northwestern Medical Group",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Carol Macpherson",
                            "role": "CONTACT",
                            "phone": "312-503-7028",
                            "email": "cmacpherson@luriechildrens.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "asFound": "Systemic Lupus Erythematosus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10411",
                    "name": "Interleukin-2",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}